B cell response and hemagglutinin stalk-reactive antibody production in different age cohorts following 2009 H1N1 influenza virus vaccination

Clinical and Vaccine Immunology

Volumn 20, Issue 6, 2013, Pages 827-834

  Sangster, Mark Y ^a   Baer, Jane ^a   Santiago, Felix W ^a   Fitzgerald, Theresa ^a   Ilyushina, Natalia A ^b   Sundararajan, Aarthi ^a   Henn, Alicia D ^a   Krammer, Florian ^c   Yang, Hongmei ^a   Luke, Catherine J ^d   Zand, Martin S ^a   Wright, Peter F ^b   Treanor, John J ^a   Topham, David J ^a   Subbarao, Kanta ^d  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; HEMAGGLUTININ STALK REACTIVE ANTIBODY; INFLUENZA VACCINE; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; INACTIVATED VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; VIRUS ANTIBODY;

2009 H1N1 INFLUENZA; ADULT; AGED; ANTIBODY PRODUCTION; ANTIGEN ANTIBODY REACTION; ARTICLE; B LYMPHOCYTE; CELLULAR IMMUNITY; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FLOW CYTOMETRY; HEMAGGLUTINATION INHIBITION; HUMAN; HUMAN CELL; INFLUENZA VACCINATION; MALE; MICRONEUTRALIZATION TITER; PRIORITY JOURNAL; ADOLESCENT; AGE; ANIMAL; BLOOD; COHORT ANALYSIS; HEMAGGLUTINATION INHIBITION TEST; IMMUNOLOGY; INFLUENZA VIRUS A H1N1; INTRAMUSCULAR DRUG ADMINISTRATION; MIDDLE AGED; SERODIAGNOSIS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; B-LYMPHOCYTES; COHORT STUDIES; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; NEUTRALIZATION TESTS; VACCINES, INACTIVATED; YOUNG ADULT;

EID: 84891384401     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00735-12     Document Type: Article

References (43)

1. Garten RJ, Davis CT, Russell CA, Shu B, Lindstrom S, Balish A, Sessions WM, Xu X, Skepner E, Deyde V, Okomo-Adhiambo M, Gubareva L, Barnes J, Smith CB, Emery SL, Hillman MJ, Rivailler P, Smagala J, de Graaf M, Burke DF, Fouchier RA, Pappas C, Alpuche-Aranda CM, Lopez-Gatell H, Olivera H, Lopez I, Myers CA, Faix D, Blair PJ, Yu C, Keene KM, Dotson PD, Jr, Boxrud D, Sambol AR, Abid SH, St George K, Bannerman T, Moore AL, Stringer DJ, Blevins P, Demmler-Harrison GJ, Ginsberg M, Kriner P, Waterman S, Smole S, Guevara HF, Belongia EA, Clark PA, Beatrice ST, Donis R, Katz J, Finelli L, Bridges CB, Shaw M, Jernigan DB, Uyeki TM, Smith DJ, Klimov AI, Cox NJ. 2009. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 325:197-201.
2. Neumann G, Noda T, Kawaoka Y. 2009. Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature 459:931-939.
3. Hancock K, Veguilla V, Lu X, Zhong W, Butler EN, Sun H, Liu F, Dong L, DeVos JR, Gargiullo PM, Brammer TL, Cox NJ, Tumpey TM, Katz JM. 2009. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N. Engl. J. Med. 361:1945-1952.
4. Skowronski DM, Hottes TS, McElhaney JE, Janjua NZ, Sabaiduc S, Chan T, Gentleman B, Purych D, Gardy J, Patrick DM, Brunham RC, De Serres G, Petric M. 2011. Immuno-epidemiologic correlates of pandemic H1N1 surveillance observations: higher antibody and lower cellmediated immune responses with advanced age. J. Infect. Dis. 203:158-167.
5. Xu R, Ekiert DC, Krause JC, Hai R, Crowe JE, Jr, Wilson IA. 2010. Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus. Science 328:357-360.
6. Zimmer SM, Burke DS. 2009. Historical perspective - emergence of influenza A (H1N1) viruses. N. Engl. J. Med. 361:279-285.
7. O'Donnell CD, Wright A, Vogel LN, Wei CJ, Nabel GJ, Subbarao K. 2012. Effect of priming with H1N1 influenza viruses of variable antigenic distances on challenge with 2009 pandemic H1N1 virus. J. Virol. 86:8625-8633.
8. Girard MP, Tam JS, Assossou OM, Kieny MP. 2010. The 2009 A (H1N1) influenza virus pandemic: a review. Vaccine 28:4895-4902.
9. McCullers JA, Van De Velde LA, Allison KJ, Branum KC, Webby RJ, Flynn PM. 2010. Recipients of vaccine against the 1976 "swine flu" have enhanced neutralization responses to the 2009 novel H1N1 influenza virus. Clin. Infect. Dis. 50:1487-1492.
10. Zhu FC, Wang H, Fang HH, Yang JG, Lin XJ, Liang XF, Zhang XF, Pan HX, Meng FY, Hu YM, Liu WD, Li CG, Li W, Zhang X, Hu JM, Peng WB, Yang BP, Xi P, Wang HQ, Zheng JS. 2009. A novel influenza A (H1N1) vaccine in various age groups. N. Engl. J. Med. 361:2414-2423.
11. Talaat KR, Greenberg ME, Lai MH, Hartel GF, Wichems CH, Rockman S, Jeanfreau RJ, Ghosh MR, Kabongo ML, Gittleson C, Karron RA. 2010. A single dose of unadjuvanted novel 2009 H1N1 vaccine is immunogenic and well tolerated in young and elderly adults. J. Infect. Dis. 202:1327-1337.
12. Greenberg ME, Lai MH, Hartel GF, Wichems CH, Gittleson C, Bennet J, Dawson G, Hu W, Leggio C, Washington D, Basser RL. 2009. Response to a monovalent 2009 influenza A (H1N1) vaccine. N. Engl. J. Med. 361:2405-2413.
13. Khurana S, Verma N, Talaat KR, Karron RA, Golding H. 2012. Immune response following H1N1pdm09 vaccination: differences in antibody repertoire and avidity in young adults and elderly populations stratified by age and gender. J. Infect. Dis. 205:610-620.
14. Thomson CA, Wang Y, Jackson LM, Olson M, Wang W, Liavonchanka A, Keleta L, Silva V, Diederich S, Jones RB, Gubbay J, Pasick J, Petric M, Jean F, Allen VG, Brown EG, Rini JM, Schrader JW. 2012. Pandemic H1N1 influenza infection and vaccination in humans induces crossprotective antibodies that target the hemagglutinin stem. Front. Immunol. 3:87. doi:10.3389/fimmu.2012.00087.
15. Li GM, Chiu C, Wrammert J, McCausland M, Andrews SF, Zheng NY, Lee JH, Huang M, Qu X, Edupuganti S, Mulligan M, Das SR, Yewdell JW, Mehta AK, Wilson PC, Ahmed R. 2012. Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly crossreactive memory B cells. Proc. Natl. Acad. Sci. U. S. A. 109:9047-9052.
16. He XS, Sasaki S, Baer J, Khurana S, Golding H, Treanor JJ, Topham DJ, Sangster MY, Jin H, Dekker CL, Subbarao K, Greenberg HB. 2013. Heterovariant cross-reactive B-cell responses induced by the 2009 pandemic influenza A/H1N1 vaccine. J. Infect. Dis. 207:288-296.
17. Miller MS, Tsibane T, Krammer F, Hai R, Rahmat S, Basler CF, Palese P. 2013. 1976 and 2009 H1N1 influenza virus vaccines boost anti-hemagglutinin stalk antibodies in humans. J. Infect. Dis. 207:98-105.
18. Wrammert J, Koutsonanos D, Li GM, Edupuganti S, Sui J, Morrissey M, McCausland M, Skountzou I, Hornig M, Lipkin WI, Mehta A, Razavi B, Del Rio C, Zheng NY, Lee JH, Huang M, Ali Z, Kaur K, Andrews S, Amara RR, Wang Y, Das SR, O'Donnell CD, Yewdell JW, Subbarao K, Marasco WA, Mulligan MJ, Compans R, Ahmed R, Wilson PC. 2011. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J. Exp. Med. 208:181-193.
19. Corti D, Voss J, Gamblin SJ, Codoni G, Macagno A, Jarrossay D, Vachieri SG, Pinna D, Minola A, Vanzetta F, Silacci C, Fernandez-Rodriguez BM, Agatic G, Bianchi S, Giacchetto-Sasselli I, Calder L, Sallusto F, Collins P, Haire LF, Temperton N, Langedijk JP, Skehel JJ, Lanzavecchia A. 2011. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 333:850-856.
20. He XS, Sasaki S, Narvaez CF, Zhang C, Liu H, Woo JC, Kemble GW, Dekker CL, Davis MM, Greenberg HB. 2011. Plasmablast-derived polyclonal antibody response after influenza vaccination. J. Immunol. Methods 365:67-75.
21. Boyce TG, Gruber WC, Coleman-Dockery SD, Sannella EC, Reed GW, Wolff M, Wright PF. 1999. Mucosal immune response to trivalent live attenuated intranasal influenza vaccine in children. Vaccine 18:82-88. (Pubitemid 29432141)
22. Pica N, Hai R, Krammer F, Wang TT, Maamary J, Eggink D, Tan GS, Krause JC, Moran T, Stein CR, Banach D, Wrammert J, Belshe RB, Garcia-Sastre A, Palese P. 2012. Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses. Proc. Natl. Acad. Sci. U. S. A. 109:2573-2578.
23. Wrammert J, Smith K, Miller J, Langley WA, Kokko K, Larsen C, Zheng NY, Mays I, Garman L, Helms C, James J, Air GM, Capra JD, Ahmed R, Wilson PC. 2008. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 453:667-671. (Pubitemid 351769295)
24. + plasma cells. Haematologica 95:1016-1020.
25. Greenbaum JA, Kotturi MF, Kim Y, Oseroff C, Vaughan K, Salimi N, Vita R, Ponomarenko J, Scheuermann RH, Sette A, Peters B. 2009. Pre-existing immunity against swine-origin H1N1 influenza viruses in the general human population. Proc. Natl. Acad. Sci. U. S. A. 106:20365-20370.
26. Faenzi E, Zedda L, Bardelli M, Spensieri F, Borgogni E, Volpini G, Buricchi F, Pasini FL, Capecchi PL, Montanaro F, Belli R, Lattanzi M, Piccirella S, Montomoli E, Ahmed SS, Rappuoli R, Del Giudice G, Finco O, Castellino F, Galli G. 2012. One dose of an MF59-adjuvanted pandemic A/H1N1 vaccine recruits pre-existing immune memory and induces the rapid rise of neutralizing antibodies. Vaccine 30:4086-4094.
27. Purtha WE, Tedder TF, Johnson S, Bhattacharya D, Diamond MS. 2011. Memory B cells, but not long-lived plasma cells, possess antigen specificities for viral escape mutants. J. Exp. Med. 208:2599-2606.
28. Dogan I, Bertocci B, Vilmont V, Delbos F, Megret J, Storck S, Reynaud CA, Weill JC. 2009. Multiple layers of B cell memory with different effector functions. Nat. Immunol. 10:1292-1299.
29. Reber AJ, Chirkova T, Kim JH, Cao W, Biber R, Shay DK, Sambhara S. 2012. Immunosenescence and challenges of vaccination against influenza in the aging population. Aging Dis. 3:68-90.
30. Nimmerjahn F, Ravetch JV. 2010. Antibody-mediated modulation of immune responses. Immunol. Rev. 236:265-275.
31. Sasaki S, Sullivan M, Narvaez CF, Holmes TH, Furman D, Zheng NY, Nishtala M, Wrammert J, Smith K, James JA, Dekker CL, Davis MM, Wilson PC, Greenberg HB, He XS. 2011. Limited efficacy of inactivated influenza vaccine in elderly individuals is associated with decreased production of vaccine-specific antibodies. J. Clin. Invest. 121:3109-3119.
32. Siegrist CA, Aspinall R. 2009. B-cell responses to vaccination at the extremes of age. Nat. Rev. Immunol. 9:185-194.
33. Brokstad KA, Eriksson JC, Cox RJ, Tynning T, Olofsson J, Jonsson R, Davidsson A. 2002. Parenteral vaccination against influenza does not induce a local antigen-specific immune response in the nasal mucosa. J. Infect. Dis. 185:878-884. (Pubitemid 34274430)
34. Dullaers M, Li D, Xue Y, Ni L, Gayet I, Morita R, Ueno H, Palucka KA, Banchereau J, Oh S. 2009. A T cell-dependent mechanism for the induction of human mucosal homing immunoglobulin A-secreting plasmablasts. Immunity 30:120-129.
35. Clements ML, Murphy BR. 1986. Development and persistence of local and systemic antibody responses in adults given live attenuated or inactivated influenza A virus vaccine. J. Clin. Microbiol. 23:66-72. (Pubitemid 16186972)
36. Sui J, Sheehan J, Hwang WC, Bankston LA, Burchett SK, Huang CY, Liddington RC, Beigel JH, Marasco WA. 2011. Wide prevalence of heterosubtypic broadly neutralizing human anti-influenza A antibodies. Clin. Infect. Dis. 52:1003-1009.
37. Khurana S, Chearwae W, Castellino F, Manischewitz J, King LR, Honorkiewicz A, Rock MT, Edwards KM, Del Giudice G, Rappuoli R, Golding H. 2010. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. Sci. Transl. Med. 2:15ra15. doi:10.1126/scitranslmed.3000624.
38. Lynch GW, Selleck P, Sullivan JS. 2009. Acquired heterosubtypic antibodies in human immunity for avian H5N1 influenza. J. Mol. Genet. Med. 3:205-209.
39. Corti D, Suguitan AL, Jr, Pinna D, Silacci C, Fernandez-Rodriguez BM, Vanzetta F, Santos C, Luke CJ, Torres-Velez FJ, Temperton NJ, Weiss RA, Sallusto F, Subbarao K, Lanzavecchia A. 2010. Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J. Clin. Invest. 120:1663-1673.
40. Staneková Z, Mucha V, Sladkova T, Blaskovicova H, Kostolansky F, Vareckova E. 2012. Epitope specificity of anti-HA2 antibodies induced in humans during influenza infection. Influenza Other Respi. Viruses 6:389-395.
41. Palese P, Wang TT. 2011. Why do influenza virus subtypes die out? A hypothesis. mBio 2(5):e00150-11. doi:10.1128/mBio.00150-11.
42. Ekiert DC, Wilson IA. 2012. Broadly neutralizing antibodies against influenza virus and prospects for universal therapies. Curr. Opin. Virol. 2:134-141.
43. Nabel GJ, Fauci AS. 2010. Induction of unnatural immunity: prospects for a broadly protective universal influenza vaccine. Nat. Med. 16:1389-1391.